You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: verteporfin plus photodynamic therapy reduces loss of vision in age related macular degeneration

https://doi.org/10.1136/ebm.9.1.20

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Wormald R, Evans J, Smeeth L, et al. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2003;(3):CD002030 (latest version 25 Feb 2003).
    OpenUrl

    
 
 Q In patients with neovascular age related macular degeneration (AMD), what is the effect of photodynamic therapy?

    Clinical impact ratings GP/FP/Primary care ★★★★☆☆☆

    METHODS

    Embedded ImageData sources:

    Cochrane Central Register of Controlled Trials, Medline, EMBASE/Excerpta Medica (to January 2003), Science Citation Index; reference lists; and contact with experts.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials that compared photodynamic therapy with placebo, no treatment, or another treatment in people with neovascular AMD.

    Embedded ImageOutcome:

    prevention of visual loss.

    MAIN RESULTS

    2 studies (948 participants) were included. Both studies compared verteporfin, 6 mg/m2 (intravenous infusion of 30 ml/10 min), plus …

    View Full Text

    Footnotes

    • For correspondence: Mr R Wormald, Moorfields Eye Hospital and Institute of Ophthalmology, London, UK. r.wormalducl.ac.uk

    • Source of funding: no external funding.